<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AA0FE0C5-C316-4213-AEB4-D57AD0698890"><gtr:id>AA0FE0C5-C316-4213-AEB4-D57AD0698890</gtr:id><gtr:name>Evgen Limited</gtr:name><gtr:address><gtr:line1>LIVERPOOL SCIENCE PARK INNOVATION CENTRE 2 , 146 BROWNLOW HILL</gtr:line1><gtr:city>LIVERPOOL</gtr:city><gtr:postCode>L3 5RF</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AA0FE0C5-C316-4213-AEB4-D57AD0698890" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>AA0FE0C5-C316-4213-AEB4-D57AD0698890</gtr:id><gtr:name>Evgen Limited</gtr:name><gtr:address><gtr:line1>LIVERPOOL SCIENCE PARK INNOVATION CENTRE 2 , 146 BROWNLOW HILL</gtr:line1><gtr:city>LIVERPOOL</gtr:city><gtr:postCode>L3 5RF</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>225000.0</gtr:offerGrant><gtr:projectCost>506900.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=720140"><gtr:id>546AB8DA-8598-49E1-A1A6-899585D37A98</gtr:id><gtr:title>Clinical Development of Sulforadex: A Novel Cancer Therapeutic</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Development of Prototype</gtr:grantCategory><gtr:grantReference>720140</gtr:grantReference><gtr:abstractText>Sulforaphane, a small molecule of botanical origin, has previously shown significant clinical promise for treating some forms of cancer. However, it is highly unstable rendering it - until now - a nonviable pharmaceutical. In a significant technical breakthrough, Evgen is now able to stabilise a synthetic sulforaphane - extending shelf life from hours to years - thereby creating the first commercially viable pharmaceutical based upon the sulforaphane molecule; a patented composition called Sulforadex&amp;reg;.

Initially, Evgen are aiming to develop Sulforadex for early stage prostate cancer, where there are currently no pharmaceutical options that could either delay or negate radical interventions such as a prostectomy. With increased diagnosis there is now an acknowledged ?over treatment? of prostate cancers, many of which could be best managed by &amp;quot;active surveillance&amp;quot; in parallel to a safe treatment such as Sulforadex. In addition to cancer, sulforaphane has been linked to the potential treatment of other medical conditions including: COPD, AMD, diabetes and cardiovascular disease.

The Project relates specifically to the initiation and execution of a ?first-in-man? trial on Sulforadex; the first time sulforaphane will have been tested in humans for safety. Furthermore, the Project will measure surrogate markers of disease (?biomarkers?) associated with anti-cancer activity yielding further intelligence prior to patient trials.</gtr:abstractText><gtr:fund><gtr:end>2013-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>225000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">720140</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>